title: Notch Inhibitor Shows Modest Efficacy.
abstract: Data from a phase I study indicate that LY3039478 is modestly effective against a range of advanced or metastatic cancers. The investigational Notch-signaling inhibitor induced partial responses and stable disease in patients with breast cancer and rare malignancies such as adenoid cystic carcinoma and leiomyosarcoma.
mesh_terms: D053829:Amyloid Precursor Protein Secretases / Q000037:antagonists & inhibitors*; D001943:Breast Neoplasms / Q000188:drug therapy* / Q000235:genetics; D003528:Carcinoma, Adenoid Cystic / Q000188:drug therapy* / Q000235:genetics; D017321:Clinical Trials, Phase I as Topic; D004791:Enzyme Inhibitors / Q000008:administration & dosage / Q000494:pharmacology; D005260:Female; D006801:Humans; D007890:Leiomyosarcoma / Q000188:drug therapy* / Q000235:genetics; D008297:Male; D051880:Receptors, Notch / Q000235:genetics; D015398:Signal Transduction / Q000187:drug effects; D054852:Small Molecule Libraries / Q000008:administration & dosage* / Q000494:pharmacology; D016896:Treatment Outcome
chemical_list: D004791:Enzyme Inhibitors; D051880:Receptors, Notch; D054852:Small Molecule Libraries; D053829:Amyloid Precursor Protein Secretases